M S A Sithole, F G Madela, T N Buthelezi-Zulu, T Lusu, K Mody, N E Nyakale, V Pillay, B P Hadebe, F Anderson
BACKGROUND: Surgery and imatinib are the mainstays of the management of gastrointestinal stromal tumours (GIST). This study aimed to analyse the outcomes in the management of GIST utilising surgery and imatinib. METHODS: Progression-free survival (PFS) and overall survival (OS) were analysed in relation to imatinib therapy, location of tumour, resection margins, type and extent of surgery. Imatinib was administered in the neoadjuvant (maximum 12 months) and adjuvant setting (minimum 36 months) and until disease progression or drug intolerance...
December 2022: South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie